Skip to content

To study the Efficacy of Thyrocompound in the management of Subclinical Hypothyroidism.

A Randomized controlled clinical Trial to study the efficacy of Thyrocompound in the management of Subclinical Hypothyroidism. - nil

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/07/070144
Enrollment
100
Registered
2024-07-08
Start date
Unknown
Completion date
Unknown
Last updated
2024-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E02- Subclinical iodine-deficiency hypothyroidism

Interventions

None listed

Sponsors

Dr Varsharani Arjun Chaudhari
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients of grade 1 subclinical hypothyroidism having serum TSH level within range of 4.9 mL/L to 10 mL/L. 2.Patients having 3 clinical symptoms of subclinical hypothyroidism among following- tiredness weakness lethargy dry skin and hair cold intolerance loss of hairs difficulty in concentration and poor memory weight gain with poor appetite constipation hoarseness of voice dypsonea menorrhagia puffy face hands and feet bradycardia

Exclusion criteria

Exclusion criteria: 1. Grade 2 subclinical hypothyroidism serum TSH level more than 10 mL/L. 2. Primary hypothyroidism caused due to thyroidectomy radioactive Iodine Therapy for Graves disease or Nodular Goiter. Radio therapy for head and neck cancer. 3. Secondary hypothyroidism 4. Patients Having history of medications like Amiodarone, Interleukin -2 Kinase inhibitor and lithium 5. Patients undergoing any known hormonal therapy other than Levothyroxine 6. Patients suffering from chronic anemia 7. Co morbid patients like known case of HTN, DM, IHD, Angina , MI 8. Patients receiving anti retro viral therapy

Design outcomes

Primary

MeasureTime frame
Effect on Weight BMI Serum TSH Total Cholesterol LDL HDL Triglycerides Tiredness weight gain in last 3 months hair loss dryness of hair and skin constipation puffiness of face muscle weakness difficulty in concentrationTimepoint: at Baseline and 13 weeks of Trial.

Secondary

MeasureTime frame
Age, sex, economical Status and Prakruti of subjects will be evaluated as a secondary outcomeTimepoint: at the end of 13 weeks

Countries

India

Contacts

Public ContactDr Popat V Jagtap

Shree Saptashrungi Ayurved Mahavidyalaya and Hospital Nashik

drpvjagtap@gmail.com9822852144

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026